Genesys International Corporation Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.In terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ( SEBI Listing Regulations ), we wish to inform that the Board of Directors of the Company at its meeting held today i.e. on Friday, May 29, 2026, inter alia, considered and approved the following:1. Audited Financial Results (Standalone & Consolidated) for the quarter and financial year ended March 31, 2026, along with the statement of Assets and Liabilities as at March 31, 2026. Copies of the following enclosed as Annexure A:a. Audited Financial Results (Standalone & Consolidated) for the quarter and financial year ended March 31, 2026. b. Auditors Report along with a Declaration in respect of unmodified opinion on the Audited Financial Results.
GENESYS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Genesys International reported audited standalone revenue of Rs 27,230 lakhs for FY2026, slightly lower than Rs 28,443 lakhs in FY2025. Consolidated revenue grew to Rs 32,781 lakhs from Rs 31,103 lakhs, driven by subsidiary performance. However, standalone profit after tax fell sharply to Rs 2,653 lakhs from Rs 6,303 lakhs, while consolidated PAT declined to Rs 3,280 lakhs from Rs 5,610 lakhs. The standalone results include an exceptional charge of Rs 509.62 lakhs due to revised employee benefit obligations under new labour codes. The company raised Rs 11,000 lakhs via QIP in May 2025. Operating cash flow was negative at Rs 1,971 lakhs for standalone, though financing activities generated Rs 13,876 lakhs from equity issuance and borrowings.
Significant profit decline year-on-year despite revenue growth on consolidated basis. Higher labour costs from new regulations and negative operating cash flow are concerns for investors. QIP funds provide some balance sheet cushion.